Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk overview
- Pancreatic cancer (PC) prevalence
- 5-year survival for major digestive cancers
- Anatomy of the pancreas
- Pancreatic adenocarcinoma
- Pancreatic cancer risk factors: low to moderate
- Role of smoking in pancreatic cancer development
- Pancreatic adenocarcinoma risk factors: high
- Definition of hereditary pancreatic cancer
- Syndromes associated with pancreatic cancer
- A pedigree of a family with pancreatic cancer
- Risk for developing pancreatic cancer
- President Jimmy Carter's family
- Adenocarcinoma: signs and symptoms
- Adenocarcinoma: additional signs and symptoms
- Current imaging tools
- Endoscopic ultrasound (EUS) for the pancreas
- Current status of PC biomarkers: CA 19-9
- CA 19-9: effects of selecting different cutoff points
- Pancreatic adenocarcinoma: precursor lesions
- Cross talk: genetics epigenetics & structure
- 12 pathways and processes genetically altered
- Cystic lesions of the pancreas
- Pancreatic cyst epidemiology
- Calculation of pancreatic cyst prevalence (USA)
- Classification of cystic neoplasms of the pancreas
- Characteristics of most common cystic lesions
- 3 patients with pancreatic cysts
- Endoscopic ultrasound (EUS)
- What do we need?
- Diagnostic features: pancreatic cystic lesions (1)
- Diagnostic features: pancreatic cystic lesions (2)
- Clinical factors that guide cyst management
- Meta-analysis of cyst features and malignancy
- Risk of pancreatic cancer in IPMNs
- Algorithm for management of suspected BD-IPMN
- Summary of cystic lesions
- Pancreatic adenocarcinoma: staging
- Stage distribution and 5-year relative survival
- Pancreatic carcinoma: treatment
- Median survival for different treatments
- Pancreatic carcinoma: palliation
- Duodenal obstruction (1)
- Duodenal obstruction (2)
- Pancreatic head cancer with biliary obstruction
- What do we need: challenges & opportunities (1)
- What do we need: challenges & opportunities (2)
- "The last lecture"
Topics Covered
- General epidemiologic data for pancreatic cancer
- Review risk factors for pancreatic cancer
- Clinical presentation and diagnostic modalities for pancreatic cancer
- Pancreatic cystic lesions
- Current status for early detection, diagnosis and staging of pancreatic cancer
- Treatment of pancreatic cancer
- Current needs: challenges and opportunities
- Update interview: Germline and somatic tumor testing for patients with pancreatic adenocarcinoma
- Update interview: Determining surgical resectability of a pancreatic adenocarcinoma
- Update interview: Neoadjuvant therapy for patients with resectable or borderline-resectable pancreatic adenocarcinoma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Brand, R. (2020, December 23). Pancreatic cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/QBNO1176.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Randall Brand, Grant/Research Support (Principal Investigator): Ambry Genetics, supplied research support to cover free genetic testing and costs associated with initiating study at our site as part of a multi-center trial. Study was not discussed in the presentation.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 46:46 min
- Update Interview Duration: 8:33 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, I'm Dr. Randall Brand.
I'm Professor of Medicine
at the University
of Pittsburgh Medical Center
in the Division of Gastroenterology,
Hepatology and Nutrition.
It's my pleasure to discuss
with you today
on the topic of pancreatic cancer.
0:17
My talk today will review some general
background on pancreatic cancer,
highlighting risk factors
for the disease,
how it clinically presents,
some of the common diagnostic modalities
used in pancreatic cancer,
review pancreatic cystic lesions,
the staging of the disease, treatment,
and then some of our current needs
for the disease.
0:45
Worldwide pancreatic cancer
causes over 300,000 deaths.
In the United States,
it's estimated that there will be
over 53,000 new patients
diagnosed with pancreatic cancer,
with majority of these dying
with a predicted almost 42,000 deaths.
In the United States,
there's about 1.4% lifetime risk
of developing pancreatic cancer,
and it's currently
the third leading cause
of cancer-related mortality
in the United States.
The vast majority of the tumors
are adenocarcinomas
accounting for over 90% with other types
including neuroendocrine,
acinar, and lymphomas.
My talk today will be focusing
on adenocarcinomas.
1:35
As you can see here,
this is a diagram showing
five-year survival rates
for major digestive diseases.
This is colon cancer where we've had
significant improvement since 1975
with rates increasing almost 20%.
This is pancreatic cancer,
and you can see since 1975
that we've only made modest gains,
and we're still under 10%
for five-year survival.
This is compared to several
of the other GI malignancies
where they despite still four
or five-year survival rates,
they're getting closer to 20%.